Theranica Reports 91% Precision in AI Migraine Forecasting Study
BRIDGEWATER, N.J. and CAESAREA, Israel — September 23, 2026 Theranica announced peer-reviewed results from a study evaluating its Your...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BRIDGEWATER, N.J. and CAESAREA, Israel — September 23, 2026 Theranica announced peer-reviewed results from a study evaluating its Your...
BRIDGEWATER, New Jersey, USA / CAESAREA, Israel, July 9, 2026 Theranica has announced a major reimbursement milestone for Nerivio®,...
